As a humanized antibody acting against human epidermal growth factor receptor 2 (HER2), trastuzumab has been approved by the FDA to treat metastatic GC, gastroesophageal junction cancer, as well as breast cancer expressing HER2 at very high levels 6, 7, 8. This evidence concerns the gene ERBB2 and gastric cancer.